Estimation of risk of nephrogenic systemic fibrosis inpatients of stage 3-5 chronic kidney disease undergoing magnetic resonance imaging with injectable gadobutrol.

Abstract

Objective: To determine the frequency of nephrogenic systemic fibrosis in patients undergoing contrast enhanced magnetic resonance imaging with gadobutrol. Study Design: Cross-sectional study. Setting: Doctors Hospital and Medical Center. Period: August 2025–January 2026. Methods: Total of 101 patients aged 20–80 years with eGFR <60 mL/min/1.73m² undergoing contrast-enhanced MRI. Non-probability consecutive sampling. Data analyzed via SPSS; qualitative variables as frequencies/percentages, quantitative as mean±SD. Chi-square test; p<0.05 significant. Results: No NSF cases observed in CKD stage 3–5 patients at 1 and 3 month. Mild acute reactions occurred in 3 patients (2.8%), all self-limiting. No significant eGFR differences by gender (p=0.301); adverse events significantly below the expected threshold (p=0.001). Conclusion: Gadobutrol is safe for contrast-enhanced MRI in moderate-to-severe CKD without mandatory pre-imaging renal assessment when administered at standard dose per international guidelines, streamlining workflows and ensuring timely, safe diagnostic access.